Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression

JOURNAL OF AFFECTIVE DISORDERS

卷:241

Article

Wilkinson, Samuel T.¹  Kiselycznyk, Carly¹  Banasr, Mounira²  Webler, Ryan D.¹  Haile, Colin^3,4  Mathew, Sanjay J.^3,4 

[1] Yale Sch Med, 100 York St,STE 2J, New Haven, CT 06511 USA

[2] CAMH, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada

[3] Baylor Coll Med, Houston, TX 77030 USA

[4] Michael E DeBakey VA Med Ctr, Houston, TX USA

关键词: Riluzole;    BDNF;    MDD;   

DOI  :  10.1016/j.jad.2018.08.075

来源: Elsevier

【 摘 要 】

Background: Serum brain-derived neurotrophic factor (BDNF) is decreased in individuals with major depressive disorder (MDD). Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties. Here we report serum (sBDNF) and plasma (pBDNF) levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in MDD. Methods: Serum and plasma BDNF samples were drawn at baseline and weeks 6 and 8 from 55 subjects randomized to adjunctive treatment with riluzole or placebo for 8 weeks. Results: Riluzole responders had lower baseline serum (19.08 ng/ml [SD 9.22] v. 28.80 ng/ml [9.63], p = 0.08) and plasma (2.72 ng/ml [1.07] v. 4.60 ng/ml [1.69], p = 0.06) BDNF compared to non-responders at a trend level. This pattern was nominally seen in placebo responders for baseline pBDNF to some degree (1.21 ng/ml [SD 1.29] v. 3.58 ng/ml [SD 1.67], p = 0.12) but not in baseline sBDNF. Limitations: A number of limitations warrant comment, including the small sample size of viable BDNF samples and the small number of riluzole responders. Conclusions: Preliminary evidence reported here suggests that lower baseline BDNF may be associated with better clinical response to riluzole.

【 授权许可】

Free